Owners, management and financials
CVR: 32657222
DKK 126,242,000
Revenue
Net result: DKK 1,955,000
NOVO NORDISK REGION AAMEO AND LATAM A/S (100%)
CVR · view owners
Hanna Elisabet Høj
Board: Thomas Rask Nielsen (chair) and 2 members
CVR · view management
Active
Founded 18 December 2009
CVR · view overview
103 employees
Annual report 2025 · average
Director role ended: Melanie Raouzeos-Haid
CVR · 12/05/2026
View the full event history
NOVO NORDISK PHARMA OPERATIONS A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 2009. The company is registered under the industry Formidlingsaktiviteter i forbindelse med specialiserede bygge- og anlægsarbejder. The management consists of Hanna Elisabet Høj. The board consists of Thomas Rask Nielsen (chair), Lars Bo Smidt and Linette Tangsgaard Nielsen. The company is owned by NOVO NORDISK REGION AAMEO AND LATAM A/S. According to the 2025 annual report, the company had an average of 103 employees. In 2025, the company reported revenue of DKK 126,242,000 and a net result of DKK 1,955,000 compared with DKK 2,298,000 the year before. Equity in the 2025 report amounted to DKK 33,422,000.
Source: annual report 2025, Danish Business Authority
The financial health of NOVO NORDISK PHARMA OPERATIONS A/S appears stable, with a consistent revenue growth trend from 98.63 million DKK in 2021 to 126.24 million DKK in 2025. However, profit has fluctuated, peaking at 5.02 million DKK in 2023 before declining to 1.96 million DKK in 2025, indicating potential challenges in maintaining profitability. The company’s equity has shown a positive trajectory, increasing from 20.54 million DKK in 2021 to 33.42 million DKK in 2025, which strengthens its financial position. While the revenue growth is promising, the declining profit margins may raise concerns about operational efficiency and cost management within the specialized construction industry.
AI-generated summary · Generated 09/06/2026
Selskabets formål er at etablere og/eller besidde filialer og ejerandele i selskaber i ind- og udland, at foretage investerings- og finansieringsvirksomhed, herunder anbringelse af kapital i virksomheder og fast ejendom i ind- og udland samt efter bestyrelsens nærmere bestemmelse at servicere sådanne selskaber og virksomheder driftsmæssigt. Selskabets formål er tillige at understøtte Novo Nordisk A/S farmaceutiske aktivitet.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 126.2M | 2M | 92.2M | 33.4M | 103 | |
| 202401/01/2024 – 31/12/2024 | 109.6M | 2.3M | 87.6M | 31.2M | 106 | |
| 202301/01/2023 – 31/12/2023 | 108.3M | 5M | 77.9M | 28.9M | 97 | |
| 202201/01/2022 – 31/12/2022 | 105.7M | 3.4M | 67.9M | 23.9M | 81 | |
| 202101/01/2021 – 31/12/2021 | 98.6M | 3.2M | 70.9M | 20.5M | 130 | |
| 202001/01/2020 – 31/12/2020 | 79.2M | 3M | 54.7M | 17.4M | 124 | |
| 201901/01/2019 – 31/12/2019 | 81M | 2.8M | 55.9M | 14.4M | - | |
| 201801/01/2018 – 31/12/2018 | 61.4M | 1.7M | 44M | 11.5M | - | |
| 201701/01/2017 – 31/12/2017 | 65.7M | 759K | 41.6M | 9.8M | - | |
| 201601/01/2016 – 31/12/2016 | 81.5M | 2.3M | 43.2M | 8.9M | - | |
| 201501/01/2015 – 31/12/2015 | 85.1M | 1.4M | 55.5M | 6.6M | - | |
| 201401/01/2014 – 31/12/2014 | 60.7M | -729K | 35M | 215K | - | |
| 201301/01/2013 – 31/12/2013 | 28.2M | 445K | 9.7M | 944K | - | |
| 201201/01/2012 – 31/12/2012 | 102M | 22K | 41.9M | 2M | 91 |
Compared to 68 companies in Formidlingsaktiviteter i forbindelse med specialiserede bygge- og anlægsarbejder
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreThe CVR number of NOVO NORDISK PHARMA OPERATIONS A/S is 32657222.
NOVO NORDISK PHARMA OPERATIONS A/S is owned by NOVO NORDISK REGION AAMEO AND LATAM A/S.
The management of NOVO NORDISK PHARMA OPERATIONS A/S consists of Hanna Elisabet Høj.
The board of NOVO NORDISK PHARMA OPERATIONS A/S consists of Thomas Rask Nielsen, Lars Bo Smidt and Linette Tangsgaard Nielsen, with Thomas Rask Nielsen as chair.
In 2025, NOVO NORDISK PHARMA OPERATIONS A/S reported revenue of DKK 126,242,000.
NOVO NORDISK PHARMA OPERATIONS A/S had an average of 103 employees in the 2025 financial year according to the annual report.
Claim this page to add your logo and social links. Free to get started.
Contact info changed: new phone: 44448888 (October 9, 2026).
As of October 8, 2026, Thomas Rask Nielsen has joined the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
As of October 8, 2026, John Francis Kuckelman has left the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
NOVO NORDISK PHARMA OPERATIONS A/S has published its annual report for 2025. Revenue came to DKK 126,242,000, and the net result was DKK 1,955,000.
Contact info changed: new phone: 44448888 (June 4, 2026).
Contact info changed: new phone: 44448888 (May 26, 2026).
As of May 12, 2026, Hanna Elisabet Høj is registered as adm. dir. of NOVO NORDISK PHARMA OPERATIONS A/S.
As of May 12, 2026, Melanie Raouzeos-Haid has stepped down as adm. dir. of NOVO NORDISK PHARMA OPERATIONS A/S.
NOVO NORDISK PHARMA OPERATIONS A/S has published its annual report for 2024. Revenue came to DKK 109,612,000, and the net result was DKK 2,298,000.
NOVO NORDISK PHARMA OPERATIONS A/S has published its annual report for 2023. Revenue came to DKK 108,302,000, and the net result was DKK 5,022,000.
As of May 23, 2024, John Francis Kuckelman has joined the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
As of May 23, 2024, Kristine Aachmann Bethe has left the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
As of June 30, 2023, Kristine Aachmann Bethe has joined the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
As of June 30, 2023, Tomas Haagen has left the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
As of June 1, 2023, Lars Bo Smidt has joined the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
As of June 1, 2023, Claus Steensen Sølje has left the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
As of June 1, 2023, Melanie Raouzeos-Haid is registered as adm. dir. of NOVO NORDISK PHARMA OPERATIONS A/S.
As of June 1, 2023, Lars Bo Smidt has stepped down as adm. dir. of NOVO NORDISK PHARMA OPERATIONS A/S.
NOVO NORDISK PHARMA OPERATIONS A/S has published its annual report for 2022. Revenue came to DKK 105,720,000, and the net result was DKK 3,365,000.
NOVO NORDISK PHARMA OPERATIONS A/S has published its annual report for 2021. Revenue came to DKK 98,630,000, and the net result was DKK 3,155,000.
NOVO NORDISK PHARMA OPERATIONS A/S has published its annual report for 2020. Revenue came to DKK 79,197,000, and the net result was DKK 3,014,000.
As of May 12, 2021, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of NOVO NORDISK PHARMA OPERATIONS A/S.
As of May 12, 2021, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of NOVO NORDISK PHARMA OPERATIONS A/S.
As of December 15, 2020, Linette Tangsgaard Nielsen has joined the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
As of December 15, 2020, Lene Moth Bang has left the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
As of August 13, 2020, Lars Bo Smidt is registered as adm. dir. of NOVO NORDISK PHARMA OPERATIONS A/S.
As of August 12, 2020, Lars Bo Smidt has stepped down as adm. dir. of NOVO NORDISK PHARMA OPERATIONS A/S.
NOVO NORDISK PHARMA OPERATIONS A/S has published its annual report for 2019. Revenue came to DKK 81,042,000, and the net result was DKK 2,825,000.
NOVO NORDISK PHARMA OPERATIONS A/S has published its annual report for 2018. Revenue came to DKK 61,361,000, and the net result was DKK 1,710,000.
As of October 1, 2018, Tomas Haagen has joined the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
As of October 1, 2018, Ole Falvig Ramsby has left the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
NOVO NORDISK PHARMA OPERATIONS A/S has published its annual report for 2017. Revenue came to DKK 65,682,000, and the net result was DKK 759,000.
As of April 25, 2018, Lene Moth Bang has joined the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
As of April 25, 2018, Karsten Munk Knudsen has left the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
NOVO NORDISK PHARMA OPERATIONS A/S has published its annual report for 2016. Revenue came to DKK 81,489,000, and the net result was DKK 2,324,000.
As of April 25, 2017, Claus Steensen Sølje has joined the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
As of April 25, 2017, Anne Mette Wiis Vogelsang has left the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
As of April 25, 2017, Lars Bo Smidt is registered as adm. dir. of NOVO NORDISK PHARMA OPERATIONS A/S.
As of April 25, 2017, Claus Steensen Sølje has stepped down as adm. dir. of NOVO NORDISK PHARMA OPERATIONS A/S.
NOVO NORDISK PHARMA OPERATIONS A/S has published its annual report for 2015. Revenue came to DKK 85,104,000, and the net result was DKK 1,377,000.
NOVO NORDISK PHARMA OPERATIONS A/S has published its annual report for 2014. Revenue came to DKK 60,709,000, and the net result was DKK -729,000.
As of April 14, 2015, Anne Mette Wiis Vogelsang has joined the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
As of April 14, 2015, Robert Janicki has left the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
As of July 1, 2014, Karsten Munk Knudsen has joined the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
As of July 1, 2014, Lars Green has left the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
NOVO NORDISK PHARMA OPERATIONS A/S has published its annual report for 2013. Revenue came to DKK 28,186,000, and the net result was DKK 445,000.
As of September 1, 2013, Claus Steensen Sølje is registered as adm. dir. of NOVO NORDISK PHARMA OPERATIONS A/S.
As of September 1, 2013, Peter Helt Jacobsen Haahr has stepped down as director of NOVO NORDISK PHARMA OPERATIONS A/S.
NOVO NORDISK PHARMA OPERATIONS A/S has published its annual report for 2012. Revenue came to DKK 102,038,000, and the net result was DKK 22,000.
As of July 1, 2011, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of NOVO NORDISK PHARMA OPERATIONS A/S.
As of July 1, 2011, A/S PSE NR. 4820 has stepped down as auditor of NOVO NORDISK PHARMA OPERATIONS A/S.
As of December 17, 2010, Peter Helt Jacobsen Haahr is registered as director of NOVO NORDISK PHARMA OPERATIONS A/S.
As of December 17, 2010, Leif Fenger Jensen has stepped down as director of NOVO NORDISK PHARMA OPERATIONS A/S.
As of December 18, 2009, A/S PSE NR. 4820 has been appointed auditor of NOVO NORDISK PHARMA OPERATIONS A/S.
As of December 18, 2009, Ole Falvig Ramsby has joined the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
As of December 18, 2009, Lars Green has joined the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
As of December 18, 2009, Robert Janicki has joined the board of directors of NOVO NORDISK PHARMA OPERATIONS A/S.
As of December 18, 2009, Leif Fenger Jensen is registered as director of NOVO NORDISK PHARMA OPERATIONS A/S.
As of December 18, 2009, NOVO NORDISK REGION AAMEO AND LATAM A/S is registered as an owner of NOVO NORDISK PHARMA OPERATIONS A/S with an ownership share of 100%.
NOVO NORDISK PHARMA OPERATIONS A/S was founded on December 18, 2009.
Companies in the same industry and area
CVR 43094807
CVR 35025081
CVR 44024152
CVR 46552318
CVR 33696167
